Unveiling Resmetirom: A systematic review and meta‐analysis on its impact on liver function and safety in non‐alcoholic steatohepatitis treatment
Abstract Background and Aim The role of Resmetirom in non‐alcoholic steatohepatitis (NASH) represents a promising therapeutic approach in addressing the growing global burden of liver disease. With NASH emerging as a leading cause of liver‐related morbidity and mortality worldwide, there is an urgen...
Saved in:
| Main Authors: | Hashim Talib Hashim, Ahmed Qasim Mohammed Alhatemi, Sania Riaz, Mohammedbaqer Ali Al‐Ghuraibawi, Arwa S. Alabide, Humza Saeed, Fatimah Abdullah Sulaiman, Mustafa Ali Abd Alhussain, Maythum Ali Shallan, Ahmed Dheyaa Al‐Obaidi, Omar Saab, Hasan Al‐Obaidi, Ali Talib Hashim, Nooraldin Merza |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2024-10-01
|
| Series: | JGH Open |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/jgh3.70025 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Drug Pipeline for MASLD: What Can Be Learned from the Successful Story of Resmetirom
by: Elizabeta Knezović, et al.
Published: (2025-02-01) -
Combination Therapy of Half-Dose Resmetirom and Metformin Attenuates Metabolic Dysfunction-Associated Steatohepatitis Through Improving Cholesterol Metabolism and Inflammation
by: Wenxiu Liu, et al.
Published: (2025-05-01) -
Resmetirom in the management of metabolic associated steatohepatitis (MASH): a review of efficacy and safety data from clinical trials
by: Ikponmwosa Jude Ogieuhi, et al.
Published: (2025-06-01) -
Comparative Analysis of Resmetirom vs. FGF21 Analogs vs. GLP-1 Agonists in MASLD and MASH: Network Meta-Analysis of Clinical Trials
by: Hazem Ayesh, et al.
Published: (2024-10-01) -
RESMETIROM PARA ESTEATO-HEPATITE ASSOCIADA À DISFUNÇÃO METABÓLICA: revisão sistemática com metanálise
by: Windson Hebert Araujo Soares, et al.
Published: (2025-03-01)